Floyd F. Petersen Sells 500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $24.08, for a total value of $12,040.00. Following the completion of the transaction, the director now directly owns 73,409 shares of the company’s stock, valued at approximately $1,767,688.72. The trade was a 0.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amphastar Pharmaceuticals Trading Up 2.6 %

Shares of AMPH stock opened at $24.50 on Friday. The stock has a 50-day moving average of $26.32 and a 200-day moving average of $35.66. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 8.17, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC increased its position in shares of Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after buying an additional 520 shares during the period. Smartleaf Asset Management LLC boosted its position in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after acquiring an additional 493 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after acquiring an additional 871 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Amphastar Pharmaceuticals during the 4th quarter worth about $38,000. Finally, GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.